UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Nov

    26

    UCB presents latest scientific research in epilepsy at American Epilepsy Society (AES) Annual Meeting

    Read More

    Nov

    20

    Closing gaps in HS care through community engagement and scientific innovation

    Read More

    Nov

    20

    UCB Receives U.S. FDA Approval for BIMZELX® (bimekizumab-bkzx) as the First IL-17A and IL-17F Inhibitor for Adults with Moderate-to-Severe Hidradenitis Suppurativa

    Read More

    Nov

    14

    New BIMZELX® (bimekizumab-bkzx) Data at ACR Convergence 2024 Highlights UCB’s Efforts to Deliver Differentiated Care for Patients with Psoriatic Arthritis and Axial Spondyloarthritis

    Read More

    Nov

    14

    A Bright Future: Prioritizing Early Diagnosis, Maintenance, and Remissions in Rheumatology

    Read More

    © 2009 - 2026 UCB, Inc. Atlanta. All rights reserved. 
    Last updated: March 2026